Medscape is available in 5 Language Editions – Choose your Edition here.


Factor XIII Deficiency

  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Perumal Thiagarajan, MD  more...
Updated: Jun 17, 2016

Practice Essentials

Factor XIII (FXIII), which was initially termed fibrin stabilizing factor, is involved in clot preservation. FXIII deficiency, an autosomal recessive disorder, is a rare but potentially life-threatening cause of a hemorrhagic diathesis. Paradoxically, alterations in FXIII may also predispose to thrombosis. FXIII participates in other physiologic processes, including wound repair and healing. Congenital FXIII deficiency is due principally to defects in the catalytic A subunit of FXIII, with more than 100 mutations throughout the factor XIII A gene identified.[1]

Thrombin, generated by reactions initiated by activated tissue factor VII/factor IX pathways, leads to clot formation. See the image below.

Coagulation reactions leading to thrombin generati Coagulation reactions leading to thrombin generation and activation of factor XIII.

Signs and symptoms

The following symptoms should trigger an evaluation for FXIII deficiency:

  • Spontaneous miscarriages early in pregnancy
  • Bleeding from the umbilical cord 1-19 days after birth
  • Easy bruising and soft tissue bleeding, particularly in association with trauma, as the infant starts to ambulate; bleeding following trauma may be immediate, delayed, and/or recurrent
  • CNS hemorrhage is common, recurs in approximately 30% of patients, and may be the initial manifestation in patients with severe FXIII deficiency
  • CNS bleeding may be preceded by head trauma in children, while adults may develop a CNS bleed in the absence of obvious trauma
  • Symptoms typical of any CNS event may be present (eg, headaches, seizures, vomiting, focal neurologic defects); symptoms may be acute at onset or may be superimposed on residual findings of a past bleed
  • Menorrhagia and intra-abdominal bleeding during menses
  • Bleeding into joints
  • Poor wound healing, although described, is less common
  • Autoantibodies to FXIII are an acquired cause of a bleeding diathesis; these may be triggered by isoniazid, so a detailed drug history is essential

Bleeding into joints

  • May be precipitated by trauma
  • Reports exist of recurrent target joint bleeds, but destructive changes in the joints are uncommon [2]
  • Spontaneous joint and extensive muscle bleeding, characteristic of patients with severe hemophilia, are uncommon in patients with severe FXIII deficiency

Physical findings

Physical findings depend on the site at which bleeding develops and include the following:

  • Bleeding from the umbilical cord after birth usually manifests with persistent oozing, which may start a few days after birth
  • Findings associated with CNS bleeding depend on the location of the bleeding; trauma may precede the event, with additional findings, a new CNS bleed may be superimposed on residual findings related to a prior bleed
  • Findings in patients with bruising and soft tissue bleeding are similar to those seen in other patients; it is uncommon to find the large hematomas or joint bleeds characteristic in patients with severe hemophilia
  • Female patients may present with vaginal spotting or bleeding during early pregnancy, preceding a spontaneous miscarriage
  • Persistent, delayed, or recurrent bleeding may occur at sites of trauma or surgery
  • Poor wound healing may be noted
  • Acquired causes of FXIII deficiency, such as DIC and liver disease, present in a well-recognized manner

See Clinical Presentation for more detail.


The following routine tests are the first step in the evaluation of any bleeding disorder:

  • aPTT
  • PT
  • Thrombin
  • Clottable fibrinogen level
  • Platelet count
  • Bleeding time (after ascertaining that the patient was not on antiplatelet drugs for at least the preceding 5 d)

However, these tests cannot be used to screen for FXIII deficiency because the results would be within reference ranges in a patient with isolated severe FXIII deficiency.[3]

Qualitative screening test for severe FXIII deficiency

  • Assessment of clot solubility in 5M urea or 1% monochloroacetic acid
  • Lysis of thrombin and Ca2+ - induced clot within a few hours suggests severe FXIII deficiency, provided that fibrinogen levels are qualitatively and quantitatively within reference range
  • The thrombin-clottable fibrinogen test can be used to exclude hypofibrinogenemia and dysfibrinogenemia, which cause false-positive results on the 5M urea solubility test

Quantitative testing

If the 5M urea solubility test demonstrates positive results, this finding should be confirmed by quantitating FXIII activity using a monodansylcadaverine or putrescine incorporation assay.

A new sensitive assay used to quantitate FXIII activity is based on monitoring the amount of ammonia (NH3) released by using glutamate dehydrogenase and nicotinamide adenine dinucleotide phosphate during the transamidation reaction (cross-linking) by FXIII. Another new and sensitive colorimetric assay is based on incorporation of 5-(biotinamido) pentylamine into fibrin/fibrinogen.[4]

In addition, a2PI and plasminogen activator inhibitor-1 assays should be performed to exclude abnormalities in the fibrinolytic pathway, which accelerate clot lysis. Sodium dodecylsulfate polyacrylamide gel electrophoresis under reducing conditions has been used to assess the presence of cross-linked g or a chains of fibrin, which is a reflection of FXIII activity. The studies must be performed by laboratory personnel with special expertise.

Testing for inhibitors

  • Repeat the urea solubility test with mixtures containing varying proportions of patient and normal plasma to differentiate between a deficiency or an inhibitor as the cause of a positive result; serum may be substituted for plasma in the test
  • Semiquantitation of the susceptibility of the fibrin clot to fibrinolysis can be obtained by adding iodine-125-labeled fibrinogen, tissue plasminogen activator, thrombin, and Ca 2 + to the patient's plasma, with measurement of the time to 50% clot lysis

Prenatal diagnosis

  • Chorionic villous sampling at approximately 10-12 weeks of gestation or amniocentesis at 16-20 weeks of gestation can be performed to obtain fetal cells for DNA analysis or for linkage studies
  • If DNA analysis cannot be performed, fetal blood obtained by fetoscopy at approximately 20 weeks of gestation can be used
  • Perform these procedures only after intense genetic and obstetric counseling of the parents

See Workup for more detail.


FXIII replacement is used to treat bleeding, to prevent perioperative bleeding during elective surgical procedures or, prophylactically, to prevent recurrent bleeding, as in CNS or joint hemorrhages. Serial monitoring of achieved FXIII levels is essential to document the adequacy of any therapy.

FXIII concentrates for replacement are as follows:

  • Plasma-derived virus-inactivated human FXIII concentrate (Corifact, in the United States; Fibrogammin P in Europe, South America, South Africa, and Japan); a second FXIII concentrate (Bio Products Laboratory, Elstree, Hertfordshire, UK) is available on a per-patient request
  • Recombinant FXIII A-subunit, recombinant (Tretten)

Minor bleeding, as from cuts and abrasions, may respond to conservative measures, such as pressure, ice, and use of antifibrinolytic drugs. Avoidance of trauma and nonsteroidal anti-inflammatory drugs (NSAIDs) is helpful in reducing bleeding events.

Treatment of patients with inhibitors

  • FXIII dose depends on the characteristics of the inhibitor
  • Also treat the underlying disorder and, when appropriate, use immunosuppressive agents, including the newer B-cell-directed monoclonal antibodies.
  • Note that spontaneous disappearance of acquired inhibitors is part of their natural history, and the use of milder less toxic immunomodulators, such as steroids, may suffice
  • Simple immediate ancillary measures of ice, pressure, ace wrap, immobilization of the affected joint, and avoidance of NSAIDs may suffice in some cases

See Treatment and Medication for more detail.



The hemostatic system, consisting of blood vessels and blood, plays a crucial role in human survival. The importance of the plasma coagulation system in protecting life and preventing further blood loss following transection of a blood vessel has been understood for a long time. Blood normally is maintained in a fluid state, without evidence of bleeding or clotting. The presence of a bleeding diathesis in families with an X-linked pattern of inheritance of the disorder has been recognized for hundreds of years.

The recognition of factor deficiencies as the cause of hemophilias spurred investigations into the causes of other bleeding disorders and led to progress in understanding normal hemostasis. Knowledge of the fact that blood clots that are formed in the presence of calcium are stronger, insoluble in alkali, and resistant to proteolytic degradation led to the concept of insoluble clots in the earlier part of the last century.

In 1948, Laki and Lorand recognized that a serum factor, termed fibrin stabilizing factor, was responsible for the characteristics of insoluble fibrin clots.[5] In 1960, Duckert et al described the first case of an "undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency," which was a description of the consequences of severe factor XIII (FXIII) deficiency.[6, 7]

The importance of FXIII in the process of coagulation is underscored by symptoms borne by patients who are homozygously deficient in FXIII or who have an antibody that disrupts FXIII function. Paradoxically, alterations in FXIII may predispose patients to thrombosis. Based on all available data, FXIII is clearly involved in the clot preservation side of the delicate balance between clot formation and stability and clot degradation. FXIII participates in other physiologic processes, including wound repair and healing. The many functions of FXIII and the disruptions of those functions by mutations in the genes coding for FXIII are the subjects of on-going investigations.[8, 9, 10]

Gene polymorphisms are being evaluated for their influence on susceptibility to venous and arterial thromboembolism.[11] Variants of coagulation factors, including factor XIII Val34Leu, have been implicated in influencing susceptibility to thromboembolic diseases.[12]

There is a question as to whether factor XIII Val34Leu polymorphism is protective against idiopathic venous thromboembolism.[13] The substitution of leucine for valine at amino acid position 34 of the factor XIII gene, commonly referred to as FXIII Val34Leu polymorphism, has been reported to confer protection against venous thromboembolism. However, the results of a recent study of white Canadian study population do not support an independent association of the FXIII Val34Leu polymorphism with idiopathic venous thromboembolism.

An association may exist between the factor XIII Leu allele and a modest protective effect against AMI and may provide useful information in profiling susceptibility to myocardial infarction.[14]

Factor XIII has a variety of uses, potential and real. Plasma levels of factor XIII were found decreased in children with Henoch–Schönlein purpura having severe abdominal symptoms. Thus, it has been suggested that measurement of factor XIII level may be of value to detect the vasculitic process of Henoch–Schönlein purpura before the rash occurs or long after it has disappeared in patients with isolated abdominal or scrotal problems.[15, 16]

Immunohistochemistry may show factor XIIIa (FXIIIa).[17] FXIIIa-positive dermal dendritic cells were increased in a variety of skin tumors, including dermatofibromas.

Severe factor XIII deficiency, a rare autosomal recessive coagulation disorder, is associated with a relatively common prevalence of F13B gene defects, at least within the German population. The regions in and around the cysteine disulphide bonds in the FXIII-B protein at the sites of frequent mutations.[18]

FXIIIs aids immobilization and killing of bacteria as well as phagocytosis by macrophages, likely functioning as part of the innate immune system.[19]

Use of relatively new specific FXIII assays are pivotal to avoid missing the diagnosis of FXIII deficiency, a rare but potentially life-threatening disorder.[20]



Structure, production, and half-life of FXIII

Plasma FXIII is a heterotetramer consisting of 2 identical proenzyme subunits (A2) and 2 identical carrier protein subunits (B2). Subunit A contains the catalytic site, the activation peptide, a calcium-binding site, and free sulfhydryl (SH) groups. Subunit B, a glycoprotein, acts as a carrier protein that stabilizes subunit A, binds the zymogen (subunit A) to fibrinogen, and acts as a brake on FXIII activation.[21, 22] Subunit B circulates in plasma as part of the tetramer A2 B2 and as a free B2 dimer; all of plasma subunit A is complexed with subunit B. The concentration of subunit A in plasma is 15 mg/mL, while that of subunit B is 21 mg/mL. Much of FXIII circulates in blood in association with fibrinogen.[23, 24]

Platelet FXIII (an A2 homodimer) constitutes approximately 50% of total FXIII activity in blood. Plasma FXIII has a long half-life of approximately 9-14 days. A similarity exists between a portion of the carboxy terminal (C terminal) domain of FXIII and the receptor-binding region of a2 -macroglobulin. The complex of a2 -macroglobulin and its substrate protease is removed from the circulation by binding to its receptor in the liver and other tissues; therefore, as has been suggested, FXIII also may be removed from the circulation by a similar mechanism.[25, 26] Some features of the A and B chains of FXIII are listed below. Monoclonal antibodies and naturally occurring inhibitors are used to elucidate structure-activity relationships.

Bone marrow cells, megakaryocytes, and monocytes/macrophages synthesize FXIII, with a possible role for hepatocytes in the synthesis of subunit A. Subunit B is synthesized by the liver. Tissue transglutaminase, the intracellular form of FXIII, consists of the A2 subunit (an A2 homodimer) and is present in a variety of cells including platelets, megakaryocytes, monocytes/macrophages, and in the liver, placenta, uterus, prostate, and dermal dendrocytes.[27] Red cells contain a transglutaminase that is activated by Ca2+ but is different from plasma transglutaminase in its cross-linking activity and can cross-link fibrinogen as well as fibrin. Trapped erythrocytes release FXIII when red cells lyse, providing additional cross-links to the aging thrombus.[21]

Table. Some Features of the A and B Chains of Factor XIII (Open Table in a new window)

Properties A Chain B Chain
Plasma FXIII Has 2 A chains Has 2 B chains
Plasma level Approximately 15 mg/mL Approximately 21 mg/mL
Chains are free in plasma No. All bound to B chain and present as an A2 B2 tetramer Yes. Excess B chain present in plasma as a B2 dimer
Chain contains the catalytic site Yes No
Chain is the carrier protein No Yes
Chain acts as a brake on FXIII activation No Yes
Cellular FXIII Has 2 A chains (A2 dimer) Has no B chains
Mutations can lead to decreased FXIII activity Yes Yes

Comparative biology shows that transglutaminases are distributed widely in nature and may represent the prototype for the evolution of clotting enzymes.[28] Partial homology of plasma FXIII exists with several proteins including tissue and keratinocyte transglutaminases, erythrocyte transglutaminase, and the hemocyte transglutaminase of the horseshoe crab and other zymogens of the same family.

A recent example is from the crystal structure of transglutaminase of the Red Sea bream, which shows that its active site and overall structure resemble that of human FXIII.[29] These homologies attest to conservation of the enzyme during evolution. Since the gene structures are similar, it is believed that they evolved from a common ancestor. Subunit B contains 10 repeating "sushi" units linked by disulfide bonds; the function of the sushi unit is unknown. Sushi structures are present in at least 26 proteins, including proteins in the horseshoe crab and in the vaccinia virus.


Thrombin, generated by reactions initiated by activated tissue factor VII/factor IX pathways (as illustrated in the first diagram below), leads to clot formation. Thrombin releases fibrinopeptide A from the a chain of fibrinogen, then fibrinopeptide B from the b chain of fibrinogen. Fibrin monomers (formed following the release of fibrinopeptides) polymerize spontaneously; this is followed by development of a complex branching clot as a result of the actions of activated FXIII (FXIIIa).[30] The sequence of these final steps is found in the second chart below.

Coagulation reactions leading to thrombin generati Coagulation reactions leading to thrombin generation and activation of factor XIII.
Final steps in clot formation (from article: Facto Final steps in clot formation (from article: Factor XIII).

Thrombin starts the process of FXIII activation by cleaving an activation peptide from subunit A. The subsequent Ca2+ -dependent dissociation of subunit B allows FXIII activation to proceed. Calcium is important for activation of the zymogen (both FXIII and tissue transglutaminase require Ca2+), conformational changes, and opening of the catalytic site of FXIII to its substrate. Calcium also provides physical stability as determined by x-ray crystallography, computer modeling, and other studies; all of the changes allow the active subunit A to perform its functions optimally.[21, 31, 32]

When activated by thrombin, tissue FXIII functions in the same manner as plasma FXIIIa. Platelet FXIII undergoes nonproteolytic activation following the platelet activation-induced rise in cytosolic Ca2+. Activation of the red cell enzyme occurs upon exposure to Ca2+, and red cells that are present in the fibrin clot lyse and release their FXIII as the clot ages. Several controls in the complex activation process focus the actions of FXIIIa on fibrin rather than on fibrinogen. Cross-linking of polymerized soluble fibrin by FXIIIa is the final step in hemostasis, as illustrated in the following chart. For extensive details of this activation process, the reader is referred to two recent reviews by Lorand.[21, 28] Note the image below.

Activation of factor XIII and generation of insolu Activation of factor XIII and generation of insoluble cross-linked fibrin. Adapted from Lorand L. Ann N Y Acad Sci. 2001;936:291-311.

Role of FXIII in cross-linking and resistance to lysis

FXIIIa cross-links the lysine of one g chain in the fibrin polymer with the glutamine of another g chain by transamidation, releasing ammonia in the process. Additional cross-links occur between a-a chains, a-g chains, a chains-a2 -plasmin inhibitor (a2 PI), and a chains-fibronectin. As a result of the extensive cross-linking actions of FXIIIa, the clot structure of fibrin polymers increases in complexity from dimers to trimers to tetramers.

The g chains of fibrinogen and fibrin normally bind to the platelet membrane glycoprotein IIb/IIIa complex. The same g chains are subject to cross-linking by FXIIIa; therefore, cross-linking also occurs between fibrin and the platelet membrane. Both plasma FXIIIa and platelet FXIIIa cross-link fibrin polymers, but under physiologic conditions, platelet FXIII is believed to play a minor role.[33] Red cell FXIII is responsible for hybrid cross-linking of a-g chains, in contrast to the actions of plasma FXIII.

Dysfibrinogenemias and dyshypofibrinogenemias result in alterations in fibrin (substrate for FXIIIa), which can interfere with the ability of FXIII to cross-link fibrin. A reduction in available fibrin resulting from afibrinogenemia can have the same effect. Conversely, increased fibrinogen levels have been identified as a risk factor for thrombosis.

Mechanisms of this risk were elucidated by a fibrinolysis assay containing purified components. The assay showed that lysis of fibrin decreased as fibrinogen levels increased, and the presence of a minor common variant of fibrin (g') is associated with accelerated cross-linking, which made the clot resistant to proteolysis by both plasmin and trypsin. Increased clot stability also was believed to result from increased concentration of FXIII in the clot. Non-cross-linked fibrin potentiates activation of FXIII by thrombin; thus, the substrate potentiates its enzyme, further contributing to clot stability.[24, 34, 35]

Cross-linking of a2 PI to a chains of fibrin by FXIIIa brings the principal inhibitor of plasmin to the site of the clot, ensuring resistance of the clot to proteolysis. Inhibition of a2 PI in in vitro systems leads to enhanced clot lysis. In humans, deficiency of a2 PI results in a bleeding disorder because of vulnerability of the fibrin clot to prompt degradation by plasmin. The formation of highly cross-linked a-fibrin polymers in the presence of high concentrations of FXIIIa produces clots that are highly resistant to fibrinolysis.[36]

Fibronectin, an adhesive protein, is a large component (approximately 4%) of the proteins in a fibrin clot, is present in plasma and cells, and is subject to cross-linking by both plasma and cellular FXIII. Cross-linking of fibronectin to fibronectin and fibronectin to fibrin is accomplished by FXIIIa, with fibronectin contributing to increased fiber size, density, and strength of the clot. FXIIIa also cross-links actin to fibrin and actin to myosin. Cross-linking of intracellular structural proteins is involved in clot retraction and cell migration. This complex gel network created by the actions of FXIII plays an important role in wound healing, cell adhesion, and cell migration. All of these cross-linking reactions impart increased mechanical strength to the clot, contributing to clot retraction and resistance of the clot to degradation by plasmin and providing an explanation for the known plasmin resistance of older clots.

Many other proteins function as substrates for FXIIIa, including von Willebrand factor (vWF), factor V (FV), thrombospondin, gelsolin, vitronectin, vinculin, lipoprotein (a), and collagen (FXIIIa cross-links collagen with fibronectin and vWF, attaches the clot to the vessel wall, impacts tissue repair, increases resistance of collagen to proteolysis, and modulates synthesis of collagen by fibroblasts). Thus, FXIII plays a role in a wide array of cross-linking reactions involving plasma proteins at the intracellular level, impacting many different functions.

Factors affecting level and activity of FXIII

When quantitative amine incorporation assays became available, healthy people were found to have an 8-fold spread in FXIIIa activity.[37] In recent studies of FXIII antigen and activity in humans, no correlation was found between these two parameters. During the search for an explanation, 23 unique FXIIIa genotypes were found. The Leu34 and Leu564 variants gave rise to increased specific activity; the Phe204 variant lowered specific activity. Other mutations gave rise to low, high, or median FXIII-specific activity, and some variants had no effect.[38, 39]

In a study of the variability of FXIII levels in racial groups, FXIII activity was found to be higher in Asian Indians (male and female) than in their Chinese counterparts, accounting for approximately one fourth of the variability. Common genetic polymorphisms in the A and B chains appeared to contribute to the differences.[40] An influence exerted by acquired factors was evident in the higher FXIII levels found in women who smoked 20 or more cigarettes per day during a normal pregnancy than was found in nonsmokers, with a lesser drop in the second half of pregnancy.[41]

Role of FXIII in pregnancy

In the latter half of pregnancy, some drop in FXIII levels is normal, but severe (homozygous) FXIII deficiency is a cause of recurrent miscarriages. In a study of gestational tissues, FXIII was found in the decidual layer of the placenta, while FXIII secretion was evident in cultures of round-shaped endometrial cells. A study of early (7-8 wk) gestational tissues obtained from women without FXIII deficiency and from a woman who was homozygous for FXIII deficiency showed poorly formed cytotrophoblastic shells and Nitabuch layers, along with absence of FXIIIa in tissues obtained from the woman with FXIII deficiency. Low plasma levels of FXIII appear to correlate with low placental levels of FXIII with poor trophoblastic development, which may be the cause of spontaneous miscarriages.

It has been suggested that preventing miscarriage in patients who are severely deficient requires FXIII supplementation beginning at approximately 5 weeks of gestation because FXIII, fibrinogen, and fibronectin are necessary to anchor cytotrophoblasts invading the endometrium.[42, 43] Reduced FXIII activity resulting from the Tyr204Phe mutation has been associated with repeated miscarriages.[44]

Role of FXIII in wound healing

Physiologically, hyperpermeability induced by severe metabolic inhibition of porcine aortic endothelial cells is prevented by FXIIIa, which is similar to the maintenance of endothelial barrier function by FXIIIa despite depletion of energy or during reperfusion of ischemic rat hearts.[45] In a different system, FXIII induced epithelial wound healing by increasing cell growth by approximately 2.5 fold, leading to replacement of damaged cells.[46] Smooth muscle cell migration, an integral part of the healing process, is facilitated by FXIII. Migration of smooth muscle cells in cross-linked fibrin gels was twice the migration seen in non–cross-linked gels, demonstrating the importance of the 3-dimensional clot structure created by cross-linking in smooth muscle cell migration.[47] In humans, Fibrogammin was shown to contribute to the healing of venous leg ulcers by reducing endothelial permeability.[48]

Effects of other agents on FXIII

Nitric oxide (NO), an important diffusible molecular messenger, is increasingly recognized as having an impact on coagulation proteins. Activity of plasma transglutaminase is inhibited by NO via nitrosylation of critical thiol groups (reactive cysteine residue), resulting in inhibition of both g-chain cross-linking and insoluble clot formation. NO donors and carriers inhibit FXIII activity in a dose-dependent manner, in a purified system and in plasma. Tissue transglutaminases are involved in apoptosis, and inhibition of their activity by NO prevents apoptosis.[49, 50]

Venoms and toxins can affect clot stability. Excessive bleeding resulting from envenomation can affect the functions of FXIII in different ways. Acuthrombin A, one of two proteases in the venom of Agkistrodon acutus (five-pace snake), activates FXIII.[51] Ancrod, obtained from the venom of Agkistrodon species, causes defibrination, thereby removing the substrate for FXIII.

A severe systemic bleeding disorder may develop several hours after initial contact with 2 types of caterpillars in the Saturniidae family (from Brazil and Venezuela). Intracranial and intracerebral bleeding and renal failure may follow. In this case, FXIII reduction results from generalized disseminated intravascular coagulation (DIC) induced by several activities directed against the hemostatic mechanism, including a FXIII proteolytic-urokinase–like activity.[52] Tridegin, a peptide inhibitor of FXIII present in the saliva of an Amazon leech (Haementeria ghilianii) accelerates fibrinolysis by inhibiting FXIIIa; tridegin is under investigation as a potential new antithrombotic agent. Destabilase, an enzyme present in the leech, hydrolyzes g-g fibrin cross-links and breaks down blood clots.[53]

Simvastatin is a commonly used cholesterol-lowering agent. A non–antibody-mediated drug-induced reduction in FXIII activity as part of a broader reduction in hemostatic activation has been suggested to be the reason for the proven antithrombotic efficacy of simvastatin in clinical trials.[54] Blood samples were obtained sequentially every 30 seconds from a bleeding time cut in patients with coronary artery disease, before and 3 months after simvastatin treatment. Samples were analyzed for the time-course drop in fibrinogen levels and activation of factors II, V, and XIII by quantitative Western blot analyses. Simvastatin, independent of its effects on cholesterol, significantly reduced the rate of blood clotting, as evidenced by reduced formation of several activation products including FXIIIa.

Several selective synthetic inhibitors have been shown to prevent the ability of FXIIIa to stabilize a clot, thereby reducing clot strength (clot stiffness, viscoelastic modulus) to approximately 20% of normal (values similar to those seen in patients with severe FXIII deficiency). Rapid lysis of these clots occurred following in vitro exposure to thrombolytic agents.[28] Imidazolium derivatives, a new class of compounds, specifically inhibit both FXIII-induced formation of a-chain polymers and the incorporation of a2 PI into the a chain of fibrin, resulting in accelerated clot lysis.[10, 55]

Specific monoclonal antibodies to FXIII have provided similar benefits by reducing the viscoelastic properties and by enhancing clot lysis. They also have been used to modify disease states. The beneficial effect of the absence of cross-linked fibrin on pathophysiologic processes was proven in an animal model of widespread thrombosis. FXIIIa deficiency induced in rabbits by pretreatment with a specific monoclonal antibody before induction of a generalized Schwartzman reaction protected them from the deleterious effects of widespread microvascular thrombosis. The protection resulted from the ability of the fibrinolytic system to effectively degrade non–cross-linked thrombi.[56] These data add support to the author's speculation many years ago of the potential use of drugs that inhibit cross-linking as a method of prophylaxis in venous thromboembolic disease.

The biochemical basis and potential for using modifiers of fibrin stabilization in improved thrombolytic therapies are discussed in a recent review by Lorand.[28] Similar ideas have been proposed by others, expanding on the importance of fibrin structure in thrombus formation and dissolution.[57] Prospective clinical trials must prove any thromboprophylactic efficacy of altering fibrin structure using specific drugs.

Other functions of FXIII

Plasma and tissue transglutaminases have been reported to promote cell adhesion through specific integrins for 2 different tumor cell types, MOLT-3 human lymphocyte–like leukemia and melanoma cells and SW480 colon cancer cells transfected with a ligand.[58] In contrast, FXIII did not stimulate growth of cultured human tumor cells.[59] An intriguing observation is the potential use of subunit A of FXIII and FXIII activity as a tumor marker in malignant brain tumors; its presence may distinguish benign from malignant brain tumors.[60] Recently, it was shown for the first time that intranuclear accumulation and cross-linking activity of FXIIIa occurred in maturing monocytes, supporting the hypothesis that FXIIIa may be involved in cell proliferation/differentiation, chromatin structure remodeling, and even cell death.[61] Further data are needed to unravel the role of FXIII in malignancies.

An unexpected role has been postulated for FXIII in degenerative brain disorders. In Alzheimer disease and spongiform encephalopathies, the brain contains fibrils that develop from native proteins containing a discordant a helix. Human FXIII was found to form fibrils in buffered saline, suggesting that FXIII, in addition to several other proteins, can be a source of this abnormal fibrillar protein.[62]

Possible interactions between deficiencies of FXIII and thrombin-activatable fibrinolytic inhibitor

Thrombin-activatable fibrinolytic inhibitor (TAFI), a single-chain carboxypeptidase B–like zymogen, is activated by thrombin to become activated TAFI (TAFIa).[63] The importance of TAFIa in fibrinolysis is emphasized by the fact that the conversion of only 1% of the zymogen to TAFIa is sufficient to suppress fibrinolysis by approximately 60%.

TAFIa suppresses fibrinolysis by removing C-terminal lysine and arginine residues exposed in the partially degraded fibrin clot produced by plasmin. Removal of C-terminal lysine residues from fibrin reduces the rate of plasminogen activation by a number of mechanisms, attenuating fibrinolysis. This effect is counterbalanced in normal plasma by activation of protein C, which has profibrinolytic properties because of its ability to suppress thrombin generation via its major effect of degrading activated factor V (FVa), and to a lesser extent, activated factor VIII (FVIIIa).[63, 64, 65]

As illustrated in the chart below, a delicate balance usually exists between thrombus formation and thrombus resolution; thrombin secures survival of the thrombus created by its action on fibrinogen by activating TAFI, thereby inhibiting fibrinolysis. Cross-linking of fibrin induced by FXIIIa (activated by thrombin) renders the clot insoluble. FXIII deficiency results in absence of cross-linked fibrin, leading to premature lysis of the clot by the fibrinolytic system; adverse consequences result, including bleeding. Theoretically, a deficiency of TAFI leading to decreased suppression of fibrinolysis (enhanced clot lysis) can potentiate bleeding resulting from FXIII deficiency (also associated with enhanced clot lysis). Note the image below.

Postulated interaction between factor XIII and thr Postulated interaction between factor XIII and thrombin-activatable fibrinolytic inhibitor.

Cell surface–directed hemostasis

The concept of coagulation as a waterfall or cascade effect has been acknowledged for a long time, with platelets and other cell surfaces providing the anionic phospholipids needed for complex formation, so that reactions can proceed efficiently. One review proposed that coagulation is essentially a cell surface–based event.[66] Platelet FXIII is positioned appropriately to influence the process. (See the diagram below.)

Cell surfaced–directed hemostasis. Initially, a sm Cell surfaced–directed hemostasis. Initially, a small amount of thrombin is generated on the surface of the tissue factor–bearing (TF-bearing) cell. Following amplification, the second burst generates a larger amount of thrombin, leading to fibrin (clot) formation (from article: Factor XIII). Adapted from Hoffman and Monroe. Thromb Haemost. 2001;85(6):958-65.


Much work is needed, even in the clinical arena, to clarify the relationship between the exact levels of FXIII and hemorrhagic or thrombotic phenotypes. Establishing an international registry of patients deficient in FXIII would be of value in improving understanding of the protean manifestations of this uncommon disorder.



United States

Overall estimated frequency of the autosomal recessive disorder involving a severe deficiency of subunit A is approximately 1 case per 2 million population. Previously, consanguinity was believed to be necessary, but the detection of compound heterozygotes by the application of molecular techniques is changing that perception. Approximately 200 cases of FXIII deficiency have been described thus far.[67] See Other Problems to be Considered for a discussion of acquired FXIII deficiency related to diseases or inhibitors.


FXIII deficiency has been reported in many ethnic groups around the world, including persons from Canada, Europe, India, Israel, Japan, Kuala Lumpur, Pakistan, Papua New Guinea, South America, Thailand, Turkey, and the United States.

Diagnosis of disorders of FXIII inhibitors, which may have been missed in the past, is increasing as more laboratory support becomes available around the world. An increasing use of isoniazid (INH) to combat a worldwide rise in incidence of tuberculosis could contribute to an increased incidence of FXIII inhibitors in patients.

Variability in the distribution of mutations is exemplified by existing data, ie, significant ethnic heterogeneity was found in a Brazilian population in which the Val34Leu mutation was present in 51.2% of American Indians, 44% of whites, 28.9% of Africans, and in only 2.5% of Japanese Asians.[68]



Umbilical bleeding starting in the first few days after birth, recurrent intracranial bleeding, and recurrent early miscarriages are hallmarks of FXIII deficiency.

Approximately 30% of central nervous system (CNS) bleeding is recurrent, and approximately 50% of CNS bleeding may be fatal, but the severity of bleeding varies from family to family. Posttraumatic bleeding may be immediate, delayed, or recurrent. Traumatic joint bleeding may develop. Poor wound healing has been described, although this is not a universal finding.

Cryoprecipitate and fresh frozen plasma (FFP) provide a source of FXIII for most patients. All plasma-derived products carry risks of transmitting hepatitis, HIV, parvovirus B19, transfusion transmitted virus (TTV), and prion-induced (new variant Creutzfeldt-Jacob disease [nvCJD]) illnesses (see Complications and Medscape Reference article Factor VIII for more information). Plasma-derived FXIII concentrates are being tested at centers. Recombinant factor XIII (rFXIII) subunit A concentrates are yet to be tested widely.

Development of FXIII inhibitors (alloantibodies or autoantibodies) is associated with significant morbidity and mortality.

Pregnant women with FXIII deficiency have a significant risk of miscarriage, placental abruption, and postpartum hemorrhage without prophylaxis.[69]

Race-, sex-, and age-related demographics

No racial predilection exists for FXIII deficiency. FXIII deficiency has been reported widely. The restriction of certain polymorphisms to specific populations should be expected.

Since it is an autosomal disorder, homozygous FXIII deficiency occurs in either sex. Acquired inhibitors to FXIII can present in either males or females.

Physiologically, reduced levels of FXIII are found in healthy newborns, with a gradual rise in levels into the reference range. Premature infants have lower values than full-term neonates. FXIII levels drop in the latter half of a normal pregnancy.

Severe FXIII deficiency may present with bleeding from the umbilical cord after birth. Easy bruising and delayed and recurrent bleeding after trauma begin in childhood. Oral bleeding can begin with teething and cuts or abrasions to the lips, tongue, and frenulum. Bleeding remains a problem throughout life and requires replacement therapy. FXIII deficiency acquired as a result of autoantibodies has been reported in the older population, as has acquired hemophilia A. Both drug-induced autoantibodies and alloantibodies have been reported in patients who are severely deficient and receiving replacement therapy.

Contributor Information and Disclosures

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.


Pere Gascon, MD, PhD Professor and Director, Division of Medical Oncology, Institute of Hematology and Medical Oncology, IDIBAPS, University of Barcelona Faculty of Medicine, Spain

Pere Gascon, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, New York Academy of Medicine, New York Academy of Sciences, Sigma Xi

Disclosure: Nothing to disclose.

Elzbieta Klujszo, MD Head of Department of Dermatology, Wojewodzki Szpital Zespolony, Kielce

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald A Sacher, MB, BCh, FRCPC, DTM&H Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, FRCPC, DTM&H is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society on Thrombosis and Haemostasis, Royal College of Physicians and Surgeons of Canada, American Clinical and Climatological Association, International Society of Blood Transfusion

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: GSK Pharmaceuticals,Alexion,Johnson & Johnson Talecris,,Grifols<br/>Received honoraria from all the above companies for speaking and teaching.

Chief Editor

Perumal Thiagarajan, MD Professor, Department of Pathology and Medicine, Baylor College of Medicine; Director, Transfusion Medicine and Hematology Laboratory, Michael E DeBakey Veterans Affairs Medical Center

Perumal Thiagarajan, MD is a member of the following medical societies: American College of Physicians, American Society for Clinical Investigation, Association of American Physicians, American Society for Biochemistry and Molecular Biology, American Heart Association, American Society of Hematology, Royal College of Physicians

Disclosure: Nothing to disclose.

Additional Contributors

Paul Schick, MD Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Society of Hematology

Disclosure: Nothing to disclose.


Rajalaxmi McKenna, MD, FACP Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems

Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis

Disclosure: Nothing to disclose.

  1. Shanbhag S, Ghosh K, Shetty S. Genetic basis of severe factor XIII deficiency in a large cohort of Indian patients: Identification of fourteen novel mutations. Blood Cells Mol Dis. 2016 Mar. 57:81-4. [Medline].

  2. Thakker S, McGehee W, Quismorio FP Jr. Arthropathy associated with factor XIII deficiency. Arthritis Rheum. 1986 Jun. 29(6):808-11. [Medline].

  3. McKenna R. Abnormal coagulation in the postoperative period contributing to excessive bleeding. Med Clin North Am. 2001 Sep. 85(5):1277-310, viii. [Medline].

  4. Wilmer M, Rudin K, Kolde H, et al. Evaluation of a sensitive colorimetric FXIII incorporation assay. Effects of FXIII Val34Leu, plasma fibrinogen concentration and congenital FXIII deficiency. Thromb Res. 2001 Apr 1. 102(1):81-91. [Medline].

  5. Laki K, Lóránd L. On the Solubility of Fibrin Clots. Science. 1948 Sep 10. 108(2802):280. [Medline].

  6. Duckert F, Jung E, Sherling DH. An undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh. 1960. 5:179.

  7. Duckert F. Documentation of the plasma factor XIII deficiency in man. Ann N Y Acad Sci. 1972 Dec 8. 202:190-9. [Medline].

  8. Laki K. Our ancient heritage in blood clotting and some of its consequences. Ann N Y Acad Sci. 1972 Dec 8. 202:297-307. [Medline].

  9. Reitsma PH. Genetic principles underlying disorders of procoagulant and anticoagulant proteins. Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 59-87.

  10. Loewy AG, McDonagh J, Mikkola H, et al. Structure and function of F XIII. Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 233-48.

  11. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood. 2009 Oct 1. 114(14):2878-83. [Medline]. [Full Text].

  12. Hoppe B, Tolou F, Dörner T, Kiesewetter H, Salama A. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost. 2006 Oct. 96(4):465-70. [Medline].

  13. Wells PS, Anderson JL, Rodger MA, Carson N, Grimwood RL, Doucette SP. The factor XIII Val34Leu polymorphism: is it protective against idiopathic venous thromboembolism?. Blood Coagul Fibrinolysis. 2006 Oct. 17(7):533-8. [Medline].

  14. Shafey M, Anderson JL, Scarvelis D, Doucette SP, Gagnon F, Wells PS. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost. 2007 Apr. 97(4):635-41. [Medline].

  15. Shin JI, Lee JS. Severe gastrointestinal vasculitis in Henoch-Schoenlein purpura: pathophysiologic mechanisms, the diagnostic value of factor XIII, and therapeutic options. Eur J Pediatr. 2007 Nov. 166(11):1199-200; author reply 1201. [Medline].

  16. Shin JI, Lee JS. Could measurement of factor XIII level detect the vasculitic process of Henoch-Schönlein purpura without skin rash?. Acta Paediatr. 2008 Apr. 97(4):395. [Medline].

  17. Kuroda K, Tajima S. Proliferation of HSP47-positive skin fibroblasts in dermatofibroma. J Cutan Pathol. 2008 Jan. 35(1):21-6. [Medline].

  18. Ivaskevicius V, Biswas A, Loreth R, et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia. 2010 Mar 10. [Medline].

  19. Ichinose A. Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol. 2012 Apr. 95(4):362-70. [Medline].

  20. Schroeder V, Kohler HP. Factor XIII Deficiency: An Update. Semin Thromb Hemost. 2013 Sep. 39(6):632-41. [Medline].

  21. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci. 2001. 936:291-311. [Medline].

  22. Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to fibrinogen molecules containing gamma chains. Biochemistry. 1996 Aug 13. 35(32):10448-53. [Medline].

  23. Greenberg CS, Shuman MA. The zymogen forms of blood coagulation factor XIII bind specifically to fibrinogen. J Biol Chem. 1982 Jun 10. 257(11):6096-101. [Medline].

  24. Mosesson M. Hereditary abnormalities of fibrinogen. Beutler E, Lichtman M, Coller BS, et al, eds. Williams Hematology. New York, NY: McGraw-Hill; 2001. 1659-71.

  25. Jenner L, Husted L, Thirup S, Sottrup-Jensen L, Nyborg J. Crystal structure of the receptor-binding domain of alpha 2-macroglobulin. Structure. 1998 May 15. 6(5):595-604. [Medline].

  26. Nagy B Jr, Simon Z, Bagoly Z, Muszbek L, Kappelmayer J. Binding of plasma factor XIII to thrombin-receptor activated human platelets. Thromb Haemost. 2009 Jul. 102(1):83-9. [Medline].

  27. Monteiro MR, Murphy EE, Galaria NA, Whitaker-Menezes D, Murphy GF. Cytological alterations in dermal dendrocytes in vitro: evidence for transformation to a non-dendritic phenotype. Br J Dermatol. 2000 Jul. 143(1):84-90. [Medline].

  28. Lorand L. Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies. Arterioscler Thromb Vasc Biol. 2000 Jan. 20(1):2-9. [Medline].

  29. Noguchi K, Ishikawa K, Yokoyama Ki, Ohtsuka T, Nio N, Suzuki E. Crystal structure of red sea bream transglutaminase. J Biol Chem. 2001 Apr 13. 276(15):12055-9. [Medline].

  30. Andersen MD, Kjalke M, Bang S, et al. Coagulation factor XIII variants with altered thrombin activation rates. Biol Chem. 2009 Dec. 390(12):1279-83. [Medline].

  31. Fox BA, Yee VC, Pedersen LC, et al. Identification of the calcium binding site and a novel ytterbium site in blood coagulation factor XIII by x-ray crystallography. J Biol Chem. 1999 Feb 19. 274(8):4917-23. [Medline].

  32. Casadio R, Polverini E, Mariani P, et al. The structural basis for the regulation of tissue transglutaminase by calcium ions. Eur J Biochem. 1999 Jun. 262(3):672-9. [Medline].

  33. Hevessy Z, Haramura G, Boda Z, Udvardy M, Muszbek L. Promotion of the crosslinking of fibrin and alpha 2-antiplasmin by platelets. Thromb Haemost. 1996 Jan. 75(1):161-7. [Medline].

  34. Moaddel M, Falls LA, Farrell DH. The role of gamma A/gamma ' fibrinogen in plasma factor XIII activation. J Biol Chem. 2000 Oct 13. 275(41):32135-40. [Medline].

  35. Weiss MS, Metzner HJ, Hilgenfeld R. Two non-proline cis peptide bonds may be important for factor XIII function. FEBS Lett. 1998 Feb 27. 423(3):291-6. [Medline].

  36. Jámbor C, Reul V, Schnider TW, Degiacomi P, Metzner H, Korte WC. In vitro inhibition of factor XIII retards clot formation, reduces clot firmness, and increases fibrinolytic effects in whole blood. Anesth Analg. 2009 Oct. 109(4):1023-8. [Medline].

  37. Lorand L, Urayama T, Atencio AC, Hsia DY. Inheritance of deficiency of fibrin-stabilizing factor (factor 13). Am J Hum Genet. 1970 Jan. 22(1):89-95. [Medline]. [Full Text].

  38. Anwar R, Gallivan L, Edmonds SD, Markham AF. Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood. 1999 Feb 1. 93(3):897-905. [Medline].

  39. Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood. 1998 Oct 15. 92(8):2766-70. [Medline].

  40. Saha N, Aston CE, Low PS, Kamboh MI. Racial and genetic determinants of plasma factor XIII activity. Genet Epidemiol. 2000 Dec. 19(4):440-55. [Medline].

  41. van Wersch JW, Vooijs ME, Ubachs JM. Coagulation factor XIII in pregnant smokers and non-smokers. Int J Clin Lab Res. 1997. 27(1):68-71. [Medline].

  42. Asahina T, Kobayashi T, Okada Y, et al. Studies on the role of adhesive proteins in maintaining pregnancy. Horm Res. 1998. 50 Suppl 2:37-45. [Medline].

  43. Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta. 2000 May. 21(4):388-93. [Medline].

  44. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol. 1999 Dec. 107(3):468-84. [Medline].

  45. Noll T, Wozniak G, McCarson K, et al. Effect of factor XIII on endothelial barrier function. J Exp Med. 1999 May 3. 189(9):1373-82. [Medline]. [Full Text].

  46. Cario E, Goebell H, Dignass AU. Factor XIII modulates intestinal epithelial wound healing in vitro. Scand J Gastroenterol. 1999 May. 34(5):485-90. [Medline].

  47. Naito M, Nomura H, Iguchi A, Thompson WD, Smith EB. Effect of crosslinking by factor XIIIa on the migration of vascular smooth muscle cells into fibrin gels. Thromb Res. 1998 May 1. 90(3):111-6. [Medline].

  48. Wozniak G, Noll T, Brunner U, Hehrlein FW. Topical treatment of venous ulcer with fibrin stabilizing factor: experimental investigation of effects on vascular permeability. Vasa. 1999 Aug. 28(3):160-3. [Medline].

  49. Catani MV, Bernassola F, Rossi A, Melino G. Inhibition of clotting factor XIII activity by nitric oxide. Biochem Biophys Res Commun. 1998 Aug 10. 249(1):275-8. [Medline].

  50. Bernassola F, Rossi A, Melino G. Regulation of transglutaminases by nitric oxide. Ann N Y Acad Sci. 1999. 887:83-91. [Medline].

  51. Huang QQ, Teng MK, Niu LW. Purification and characterization of two fibrinogen-clotting enzymes from five-pace snake (Agkistrodon acutus) venom. Toxicon. 1999 Jul. 37(7):999-1013. [Medline].

  52. Arocha-Pinango CL, Marval E, Guerrero B. Lonomia genus caterpillar toxins: biochemical aspects. Biochimie. 2000 Sep-Oct. 82(9-10):937-42. [Medline].

  53. Zavalova L, Lukyanov S, Baskova I, et al. Genes from the medicinal leech (Hirudo medicinalis) coding for unusual enzymes that specifically cleave endo-epsilon (gamma-Glu)-Lys isopeptide bonds and help to dissolve blood clots. Mol Gen Genet. 1996 Nov 27. 253(1-2):20-5. [Medline].

  54. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001 May 8. 103(18):2248-53. [Medline].

  55. Finney S, Seale L, Sawyer RT, Wallis RB. Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood- sucking leech Haementeria ghilianii. Biochem J. 1997 Jun 15. 324 ( Pt 3):797-805. [Medline].

  56. Lee SY, Chang SK, Lee IH, Kim YM, Chung SI. Depletion of plasma factor XIII prevents disseminated intravascular coagulation-induced organ damage. Thromb Haemost. 2001 Mar. 85(3):464-9. [Medline].

  57. Sidelmann JJ, Gram J, Jespersen J, Kluft C. Fibrin clot formation and lysis: basic mechanisms. Semin Thromb Hemost. 2000. 26(6):605-18. [Medline].

  58. Takahashi H, Isobe T, Horibe S, et al. Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1. J Biol Chem. 2000 Aug 4. 275(31):23589-95. [Medline].

  59. Salge U, Daubner E, Heiden M, Sietz R. Factor XIII does not stimulate growth of human cultured tumor cells. Blood Coagul Fibrinolysis. 2000 Mar. 11(2):217-8. [Medline].

  60. Molnar P, Nemes Z. Hemangiopericytoma of the cerebello-pontine angle. Diagnostic pitfalls and the diagnostic value of the subunit A of factor XIII as a tumor marker. Clin Neuropathol. 1995 Jan-Feb. 14(1):19-24. [Medline].

  61. Adany R, Bardos H, Antal M, et al. Factor XIII of blood coagulation as a nuclear crosslinking enzyme. Thromb Haemost. 2001 May. 85(5):845-51. [Medline].

  62. Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J. Prediction of amyloid fibril-forming proteins. J Biol Chem. 2001 Apr 20. 276(16):12945-50. [Medline].

  63. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995 Jun 16. 270(24):14477-84. [Medline].

  64. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995 Nov. 96(5):2534-8. [Medline].

  65. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood. 1996 Sep 15. 88(6):2093-100. [Medline].

  66. Hoffman M, Monroe DM 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001 Jun. 85(6):958-65. [Medline].

  67. HGMD. Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. Available at: Accessed April 9, 2002. [Full Text].

  68. Attié-Castro FA, Zago MA, Lavinha J, et al. Ethnic heterogeneity of the factor XIII Val34Leu polymorphism. Thromb Haemost. 2000 Oct. 84(4):601-3. [Medline].

  69. Sharief LA, Kadir RA. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia. 2013 Aug 28. [Medline].

  70. Mikkola H, Muszbek L, Laiho E, et al. Molecular mechanism of a mild phenotype in coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting partial correct splicing of FXIII A-subunit mRNA. Blood. 1997 Feb 15. 89(4):1279-87. [Medline].

  71. Greenberg DL, Davie EW. Blood coagulation factors: their complementary DNAs, genes, and expression. Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 21-57.

  72. Kangsadalampai S, Yenchitsomanus P, Chelvanayagam G, Sawasdee N, Laosombat V, Board P. Identification of a new mutation (Gly420Ser), distal to the active site, that leads to factor XIII deficiency. Eur J Haematol. 2000 Oct. 65(4):279-84. [Medline].

  73. Koseki S, Souri M, Koga S, et al. Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood. 2001 May 1. 97(9):2667-72. [Medline].

  74. Gomez Garcia EB, Poort SR, Stibbe J. Two novel and one recurrent missense mutation in the factor XIII A gene in two Dutch patients with factor XIII deficiency. Br J Haematol. 2001 Feb. 112(2):513-8. [Medline].

  75. Anwar R, Gallivan L, Trinh C, Hill F, Markham A. Identification of a new Leu354Pro mutation responsible for factor XIII deficiency. Eur J Haematol. 2001 Feb. 66(2):133-6. [Medline].

  76. Warner D, Mansfield MW, Grant PJ. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography. Thromb Haemost. 2001 Mar. 85(3):408-11. [Medline].

  77. Canavy I, Henry M, Morange PE, et al. Genetic polymorphisms and coronary artery disease in the south of France. Thromb Haemost. 2000 Feb. 83(2):212-6. [Medline].

  78. Franco RF, Middeldorp S, Meinardi JR, van Pampus EC, Reitsma PH. Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers. Br J Haematol. 2000 Oct. 111(1):118-21. [Medline].

  79. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood. 1999 Feb 1. 93(3):906-8. [Medline].

  80. Kohler HP. Role of blood coagulation factor XIII in vascular diseases. Swiss Med Wkly. 2001 Jan 27. 131(3-4):31-4. [Medline].

  81. Prata MJ, Miranda C, Rocha J, Amorim A. Allelic affinities between the F13A common gene products inferred by the analysis of an (AAAG)n STR polymorphism within the 5' untranslated region. Hum Hered. 2000 May-Jun. 50(3):189-93. [Medline].

  82. Hedner U, Ginsburg D, Lusher JM, High KA. Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia. Hematology Am Soc Hematol Educ Program. 2000. 241-265. [Medline].

  83. Coukos G, Rubin SC. Gene therapy for ovarian cancer. Oncology (Williston Park). 2001 Sep. 15(9):1197-204, 1207; discussion 1207-8. [Medline].

  84. Chandler WL, Patel MA, Gravelle L, et al. Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis. 2001 Mar. 12(2):101-8. [Medline].

  85. Holst FG, Hemmer CJ, Foth C, Seitz R, Egbring R, Dietrich M. Low levels of fibrin-stabilizing factor (factor XIII) in human Plasmodium falciparum malaria: correlation with clinical severity. Am J Trop Med Hyg. 1999 Jan. 60(1):99-104. [Medline].

  86. Matayoshi T, Omi T, Sakai N, Kawana S. Clinical Significance of Blood Coagulation Factor XIII Activity in Adult Henoch-Schönlein Purpura. J Nippon Med Sch. 2013. 80(4):268-78. [Medline].

  87. Lorand L, Velasco PT, Murthy SN, Lefebvre P, Green D. Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. Blood. 1999 Feb 1. 93(3):909-17. [Medline].

  88. Feinstein DI. Immune coagulation disorders. Coleman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001. 1003-20.

  89. Ahmad F, Solymoss S, Poon MC, Berube C, Sullivan AK. Characterization of an acquired IgG inhibitor of coagulation factor XIII in a patient with systemic lupus erythematosus. Br J Haematol. 1996 Jun. 93(3):700-3. [Medline].

  90. Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol. 1995 Jan. 48(1):34-9. [Medline].

  91. Krumdieck R, Shaw DR, Huang ST, Poon MC, Rustagi PK. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenstrom's macroglobulinemia. Am J Med. 1991 May. 90(5):639-45. [Medline].

  92. Heinle K, Adam O, Rauh G. Factor XIII insufficiency in a patient with severe psoriasis vulgaris, arthritis, and infirmity. Clin Rheumatol. 1998. 17(4):346-8. [Medline].

  93. Lorand L. Acquired inhibitors of fibrin stabilization: a class of hemorrhagic disorders of diverse origins. Anticoagulants: Physiologic, Pathologic and Pharmacologic. CRC Press; 1994. 169-91.

  94. Dorgalaleh A, Kazemi A, Zaker F, Shamsizadeh M, Rashidpanah J, Mollaei M. Laboratory Diagnosis of Factor XIII Deficiency, Routine Coagulation Tests with Quantitative and Qualitative Methods. Clin Lab. 2016. 62 (4):491-8. [Medline].

  95. Glidden PF, Malaska C, Herring SW. Thromboelastograph assay for measuring the mechanical strength of fibrin sealant clots. Clin Appl Thromb Hemost. 2000 Oct. 6(4):226-33. [Medline].

  96. Karpati L, Penke B, Katona E, Balogh I, Vamosi G, Muszbek L. A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma. Clin Chem. 2000 Dec. 46(12):1946-55. [Medline].

  97. Katona E, Haramura G, Karpati L, Fachet J, Muszbek L. A simple, quick one-step ELISA assay for the determination of complex plasma factor XIII (A2B2). Thromb Haemost. 2000 Feb. 83(2):268-73. [Medline].

  98. Killick CJ, Barton CJ, Aslam S, Standen G. Prenatal diagnosis in factor XIII-A deficiency. Arch Dis Child Fetal Neonatal Ed. 1999 May. 80(3):F238-9. [Medline]. [Full Text].

  99. Orosz ZZ, Katona E, Facsko A, Berta A, Muszbek L. A highly sensitive chemiluminescence immunoassay for the measurement of coagulation factor XIII subunits and their complex in tears. J Immunol Methods. 2010 Feb 28. 353(1-2):87-92. [Medline].

  100. Brooks M. FDA Clears Tretten for Coagulation Factor XIII Deficiency. Available at Accessed: January 6, 2014.

  101. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012 May 31. 119(22):5111-7. [Medline].

  102. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol. 1998 Nov. 5(6):372-5. [Medline].

  103. Green D. Spontaneous inhibitors to coagulation factors. Clin Lab Haematol. 2000 Oct. 22 Suppl 1:21-5; discussion 30-2. [Medline].

  104. Lorand L, Losowsky MS, Miloszewski KJM. Human factor XIII: fibrin stabilizing factor. Spaet T, ed. Progress in Hemostasis and Thrombosis. New York, NY: Grune & Stratton; 1980. Vol 5: 245-90.

  105. Abbondanzo SL, Gootenberg JE, Lofts RS, McPherson RA. Intracranial hemorrhage in congenital deficiency of factor XIII. Am J Pediatr Hematol Oncol. 1988 Spring. 10(1):65-8. [Medline].

  106. Green D, Sanders J, Wong C, et al. Coronary revascularization in the presence of an inhibitory antibody to factor XIII. Bull Intensive Crit Care. 1996. 3(3):14-6.

  107. Wiel E, Marciniak B, Wibaut B. [Recurrent hematomas and normal standard hemostasis tests]. Ann Fr Anesth Reanim. 1998. 17(1):61-4. [Medline].

  108. Kawamura A, Tamaki N, Yonezawa K, Nakamura M, Asada M. [Effect of factor XIII on intractable CSF leakage after a transpetrosal-approach operation: a case report]. No Shinkei Geka. 1997 Jan. 25(1):53-6. [Medline].

  109. Chamouard P, Grunebaum L, Wiesel ML, et al. Significance of diminished factor XIII in Crohn's disease. Am J Gastroenterol. 1998 Apr. 93(4):610-4. [Medline].

  110. Linskens RK, van Bodegraven AA, Schoorl M, Tuynman HA, Bartels P. Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis. Dig Dis Sci. 2001 Mar. 46(3):644-8. [Medline].

  111. Helio T, Wartiovaara U, Halme L, et al. Arg506Gln factor V mutation and Val34Leu factor XIII polymorphism in Finnish patients with inflammatory bowel disease. Scand J Gastroenterol. 1999 Feb. 34(2):170-4. [Medline].

  112. Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv. 2000 Feb. 55(2):103-8. [Medline].

  113. Kreilgaard L, Jones LS, Randolph TW, et al. Effect of Tween 20 on freeze-thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci. 1998 Dec. 87(12):1597-603. [Medline].

  114. Kreilgaard L, Frokjaer S, Flink JM, Randolph TW, Carpenter JF. Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid. Arch Biochem Biophys. 1998 Dec 1. 360(1):121-34. [Medline].

  115. Dickneite G, Metzner H, Nicolay U. Prevention of suture hole bleeding using fibrin sealant: benefits of factor XIII. J Surg Res. 2000 Oct. 93(2):201-5. [Medline].

  116. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood. 2012 May 31. 119(22):5111-7. [Medline].

  117. ARC. FDA-approved product circular for Pooled Plasma, Solvent-Detergent-Treated (PLAS+SD) manufactured by the American Red Cross and V.I. Technologies, Inc. 2000.

  118. ARC. PLAS+SD (pooled plasma, solvent-detergent treated). Monograph by the American Red Cross and V. I. Technologies, Inc. 1999. VIT-001A9/99:

  119. MediView Express. Recombinant therapy enhances safety and quality of life for hemophilia patients. Paper presented at: 53rd Annual Meeting of the National Hemophilia Foundation. November 16, 2001: Nashville, Tennessee.

  120. Rigas B, Hasan I, Rehman R, Donahue P, Wittkowski KM, Lebovics E. Effect on treatment outcome of coinfection with SEN viruses in patients with hepatitis C. Lancet. 2001 Dec 8. 358(9297):1961-2. [Medline].

  121. Azzi A, De Santis R, Morfini M, et al. TT virus contaminates first-generation recombinant factor VIII concentrates. Blood. 2001 Oct 15. 98(8):2571-3. [Medline].

  122. Bachmann F. Plasminogen-plasmin enzyme system. Colman RW, Hirsh J, George JN, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed. Lippincott Williams & Wilkins; 2001. 275-320.

  123. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 May 29. 358(22):2319-31. [Medline].

  124. Di Bisceglie AM. SEN and sensibility: interactions between newly discovered and other hepatitis viruses?. Lancet. 2001 Dec 8. 358(9297):1925-6. [Medline].

  125. Treisman GJ, Angelino AF, Hutton HE. Psychiatric issues in the management of patients with HIV infection. JAMA. 2001 Dec 12. 286(22):2857-64. [Medline].

  126. Urwin PJ, Mackenzie JM, Llewelyn CA, Will RG, Hewitt PE. Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK Transfusion Medicine Epidemiology Review Study. Vox Sang. 2016 May. 110 (4):310-6. [Medline].

  127. Jackson GS, Burk-Rafel J, Edgeworth JA, Sicilia A, Abdilahi S, Korteweg J, et al. Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study. JAMA Neurol. 2014 Apr. 71 (4):421-8. [Medline].

Coagulation reactions leading to thrombin generation and activation of factor XIII.
Final steps in clot formation (from article: Factor XIII).
Activation of factor XIII and generation of insoluble cross-linked fibrin. Adapted from Lorand L. Ann N Y Acad Sci. 2001;936:291-311.
Postulated interaction between factor XIII and thrombin-activatable fibrinolytic inhibitor.
Cell surfaced–directed hemostasis. Initially, a small amount of thrombin is generated on the surface of the tissue factor–bearing (TF-bearing) cell. Following amplification, the second burst generates a larger amount of thrombin, leading to fibrin (clot) formation (from article: Factor XIII). Adapted from Hoffman and Monroe. Thromb Haemost. 2001;85(6):958-65.
Gene, messenger RNA, and protein for subunit A of factor XIII. Adapted from Reitsma PH. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott Williams & Wilkins; 2001:59-87 and from Roberts HR, Monroe DM III, Hoffman M. In: Williams Hematology. McGraw-Hill Professional; 2001:1409-34.
Table. Some Features of the A and B Chains of Factor XIII
Properties A Chain B Chain
Plasma FXIII Has 2 A chains Has 2 B chains
Plasma level Approximately 15 mg/mL Approximately 21 mg/mL
Chains are free in plasma No. All bound to B chain and present as an A2 B2 tetramer Yes. Excess B chain present in plasma as a B2 dimer
Chain contains the catalytic site Yes No
Chain is the carrier protein No Yes
Chain acts as a brake on FXIII activation No Yes
Cellular FXIII Has 2 A chains (A2 dimer) Has no B chains
Mutations can lead to decreased FXIII activity Yes Yes
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.